Completed

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis (COAST-Y)

I1F-MC-RHBY - ClinicalTrials.gov - NCT03129100

The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.
How long will I be in the trial?
Your participation could last approximately 32 months and include approximately 22 visits to the study center
Email
Completed

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis (COAST-Y)

I1F-MC-RHBY - ClinicalTrials.gov - NCT03129100

The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.
How long will I be in the trial?
Your participation could last approximately 32 months and include approximately 22 visits to the study center
Email

Key Requirements

Age :

18+

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participant must have completed either study RHBV (NCT02696785), RHBW (NCT02696798),or RHBX (NCT02757352). __NOTE__: Participants from study RHBX are not eligible if they permanently discontinued ixekizumab and were receiving a tumor necrosis factor [TNF] inhibitor

Participant must agree to use a reliable method of birth control

Participants must NOT

Trial Summary

Conditions the trial is for

Axial Spondyloarthritis (Ankylosing Spondylitis)

What the trial is testing?

Ixekizumab, Placebo

Could I receive a Placebo?

yes

Enrollment Goal

750

Trial Dates

May 2017 - May 2021

Trial Phase

3

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participant must have completed either study RHBV (NCT02696785), RHBW (NCT02696798),or RHBX (NCT02757352). __NOTE__: Participants from study RHBX are not eligible if they permanently discontinued ixekizumab and were receiving a tumor necrosis factor [TNF] inhibitor

Participant must agree to use a reliable method of birth control

Participants must NOT

Trial Summary

Conditions the trial is for

Axial Spondyloarthritis (Ankylosing Spondylitis)

What the trial is testing?

Ixekizumab, Placebo

Could I receive a Placebo?

yes

Enrollment Goal

750

Trial Dates

May 2017 - May 2021

Trial Phase

3

Not the right fit? Sign up to receive updates on new Axial Spondyloarthritis (Ankylosing Spondylitis) trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

By clicking the checkbox and using the map, you agree to allow Google Maps to collect your personal information in accordance with their Privacy Policy

Axial Spondyloarthritis (Ankylosing Spondylitis) Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?